Downregulation of RIP140 in triple-negative breast cancer inhibits the growth and proliferation of cancer cells

被引:6
|
作者
Yu, Xiao-Hong [1 ]
Xue, Xiaodong [1 ]
Zhu, Xun [2 ]
Li, Xia [1 ]
机构
[1] 903 Hosp, Dept Breast Surg, 113 Middle Posit Taiping Rd, Jiangyou 421700, Sichuan, Peoples R China
[2] Soochow Univ, Affiliated Hosp 2, Dept Gen Surg, 1055 Sanxiang Rd, Suzhou 215006, Jiangsu, Peoples R China
关键词
triple-negative breast cancer; receptor interacting protein 140; proliferation; prognosis; RECEPTOR COREPRESSOR RIP140;
D O I
10.3892/ol.2018.8434
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the present study was to investigate the expression of receptor interacting protein 140 (RIP140) in triple-negative breast cancer (TNBC), and its association with the prognosis of patients with TNBC. A total of 179 patients with breast cancer were included in this study, with 41 cases of TNBC and 138 cases of non-TNBC. Immunohistochemical staining and western blotting were used to detect the protein expression of RIP140 in the cancerous and paracancerous tissues, revealing that expression of RIP140 was increased in TNBC tissues compared with non-TNBC tissues. High expression of RIP140 in breast cancer tissue was associated with a poorer survival time than low RIP140 expression. Using lentiviral transfection to downregulate RIP140 expression in MDA-MB-231 cells, the effects of RIP140 on the growth and proliferation of breast cancer cells was analyzed using subcutaneous tumors in BALB/c nude mice. Immunohistochemical staining using a Ki-67 antibody in subcutaneous tumor tissue was used to assess the proliferation of MDA-MB-231 cells. The short hairpin RNA-mediated downregulation of RIP140 in MDA-MB-231 cells suppressed the growth and the proliferation of subcutaneous tumors in BALB/c nude mice. Downregulation of RIP140 in breast cancer cells may therefore inhibit the growth and the proliferation of these cells, and may provide a therapeutic target for TNBC.
引用
收藏
页码:8784 / 8788
页数:5
相关论文
共 50 条
  • [41] Triple-Negative Breast Cancer
    Foulkes, William D.
    Smith, Ian E.
    Reis-Filho, Jorge S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20): : 1938 - 1948
  • [42] Triple-negative breast cancer
    Bartsch R.
    Ziebermayr R.
    Zielinski C.C.
    Steger G.G.
    Wiener Medizinische Wochenschrift, 2010, 160 (7-8) : 174 - 181
  • [43] Triple-Negative Breast Cancer
    Liedtke, Cornelia
    Schmutzler, Rita
    Schneeweiss, Andreas
    Loibl, Sybille
    Thill, Marc
    Heitz, Florian
    BREAST CARE, 2010, 5 (05) : 359 - 363
  • [44] Triple-negative breast cancer
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2020, 120 (08) : 22 - 23
  • [45] Triple-negative breast cancer
    Reinaldo D Chacón
    María V Costanzo
    Breast Cancer Research, 12
  • [46] CTSL, a prognostic marker of breast cancer, that promotes proliferation, migration, and invasion in cells in triple-negative breast cancer
    Zhang, Lianmei
    Zhao, Yang
    Yang, Jing
    Zhu, Yaning
    Li, Ting
    Liu, Xiaoyan
    Zhang, Pengfei
    Cheng, Jingliang
    Sun, Suan
    Wei, Chunli
    Fu, Junjiang
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [47] Proliferation of cancer stem cells in triple negative breast cancer
    Sazonov, S.
    Brilliant, A.
    Brilliant, Y.
    BREAST, 2017, 32 : S29 - S30
  • [48] Azurocidin 1 inhibits the aberrant proliferation of triple-negative breast cancer through the regulation of pyroptosis
    Lei, Shanshan
    Li, Shutong
    Xiao, Weiwei
    Jiang, Qiuping
    Yan, Shifan
    Xiao, Wen
    Cai, Jiaodi
    Wang, Jingjing
    Zou, Lianhong
    Chen, Fang
    Liu, Yanjuan
    Jiang, Yu
    ONCOLOGY REPORTS, 2023, 50 (04)
  • [49] Gonadotropin-releasing hormone receptor inhibits triple-negative breast cancer proliferation and metastasis
    Chen, Cai-Ping
    Lu, Xiang
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2022, 50 (03)
  • [50] Imipramine Induces Apoptosis and Inhibits the Metastatic Potential of Triple-negative Breast Cancer Cells
    Chen, Sheng-Kai
    Lee, Wei
    Li, Yu-Ching
    Hsu, Fei-Ting
    Chen, Wei-Ting
    ANTICANCER RESEARCH, 2023, 43 (07) : 2985 - 2994